Article
A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo
11 Nov 2021
Abstract excerpt
Abstract The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test prospective therapies in vivo. Generation of kidney organoids from Tuberous Sclerosis Complex (TSC) patient-derived-hiPSCs allows us to recapitulate a rare kidney tumor called angiomyolipoma (AML). Organoids derived from TSC2 −/− hiPSCs but not from isogenic TSC2 +/− or TSC2 +/+...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
